National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Colon and Rectal Cancer (Colorectal Cancer)

Colorectal cancer is an abnormal growth of cells in the tissues of the colon or rectum, which are parts of the digestive system. The colon and rectum form a long, muscular tube called the large intestine (also called the large bowel). The colon is the first 4–5 feet of the large intestine, and the rectum is the last several inches.

Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).

In advanced cases, colorectal cancer cells may invade surrounding tissues or spread (metastasize) to other parts of the body via the blood stream or lymph system.

Excluding non-melanoma cancers of the skin, colon and rectal (colorectal) cancer is the third most common type of cancer among men and women in the United States. It is estimated there will be more than 103,000* people newly diagnosed with colon cancer and more than 40,000* people newly diagnosed with rectal cancer in the United States in 2012.

Treatment options for colorectal cancer vary depending on the stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society; 2012

Colorectal Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with colon and rectal (colorectal) cancers. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Colorectal Cancer
Phase II
Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma
NCI-11-C-0117, NCT01333475

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux®) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
NCI-06-C-0164, NCT00326495

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
Phase I
A Phase I Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors
NCI-11-C-0075, NCT01287130

Principal Investigator:Referral Contact:
Austin G. DuffySuzanne Fioravanti
301-451-8340301-594-6544
fioravas@mail.nih.gov


  
Trial and Protocol Number
Liver Cancer
Phase I
A Phase I Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic Metastases or Primary Liver Cancers
NCI-11-C-0240, NCT01437007

Principal Investigator:Referral Contact:
Udo RudloffMelissa Walker
301-496-3098301-402-8475
walkerme@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase II
A Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy
NCI-11-C-0146, NCT01339000

Principal Investigator:Referral Contact:
Claude SportèsZetta Blacklock
301-435-5280301-594-2056
bblacklock@mail.nih.gov
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers
NCI-10-C-0166, NCT01174121

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
NCI-12-C-0056, NCT01519817

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
NCI-11-C-0061, NCT01273168

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors
NCI-10-C-0113, NCT01120288

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
No Phase
The Natural History of Solid Organ Cancer Stem Cells
NCI-09-C-0079, NCT00923052

Principal Investigator:Referral Contact:
Steven A. RosenbergMelissa Walker
1-866-820-4505 (Toll Free)301-402-8475
walkerme@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov